{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Familial+Hypercholesterolemia",
    "query": {
      "condition": "Severe Familial Hypercholesterolemia"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T15:58:03.567Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02624869",
      "title": "Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 163,
      "start_date": "2016-09-10",
      "completion_date": "2021-06-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-07-22T15:58:03.567Z",
      "location_count": 3,
      "location_summary": "The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02624869"
    },
    {
      "nct_id": "NCT01624142",
      "title": "Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Severe Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 300,
      "start_date": "2012-06-01",
      "completion_date": "2018-05-11",
      "has_results": true,
      "last_update_posted_date": "2024-05-28",
      "last_synced_at": "2026-07-22T15:58:03.567Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • New York, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624142"
    },
    {
      "nct_id": "NCT07491172",
      "title": "A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular",
        "Metabolic Disease",
        "Dyslipidemias",
        "Lipid Disorder",
        "Hypertriglyceridemia",
        "Heterozygous Familial Hypercholesterolemia (HeFH)",
        "Homozygous Familial Hypercholesterolemia (HoFH)",
        "Severe Hypertriglyceridemia (sHTG)",
        "Mixed Hyperlipemia",
        "Hypercholesterolaemia"
      ],
      "interventions": [
        {
          "name": "CTX310",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CRISPR Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 90,
      "start_date": "2024-06-21",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-07-22T15:58:03.567Z",
      "location_count": 10,
      "location_summary": "Hialeah, Florida • High Point, Florida • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "High Point",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07491172"
    },
    {
      "nct_id": "NCT00694109",
      "title": "An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lipid Metabolism, Inborn Errors",
        "Hypercholesterolemia, Autosomal Dominant",
        "Hyperlipidemias",
        "Metabolic Diseases",
        "Hyperlipoproteinemia Type II",
        "Metabolism, Inborn Errors",
        "Genetic Diseases, Inborn",
        "Infant, Newborn, Diseases",
        "Metabolic Disorder",
        "Congenital Abnormalities",
        "Hypercholesterolemia",
        "Hyperlipoproteinemias",
        "Dyslipidemias",
        "Lipid Metabolism Disorders"
      ],
      "interventions": [
        {
          "name": "Mipomersen Sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kastle Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2008-04",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-09-09",
      "last_synced_at": "2026-07-22T15:58:03.567Z",
      "location_count": 20,
      "location_summary": "Mission Viejo, California • Newport Beach, California • Bridgeport, Connecticut + 17 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694109"
    },
    {
      "nct_id": "NCT02585895",
      "title": "Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low-density Lipoprotein Cholesterol (LDL-C) Apheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2015-12-21",
      "completion_date": "2017-01-20",
      "has_results": true,
      "last_update_posted_date": "2022-11-30",
      "last_synced_at": "2026-07-22T15:58:03.567Z",
      "location_count": 4,
      "location_summary": "Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Grandville",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02585895"
    }
  ]
}